FarmavitaR+

Benchmarking key countries Brazil, Russia, India, China and Turkey

With dwindling growth rates observed in the major developed markets many pharmaceutical companies are turning towards emerging market countries in order to sustain their revenue growth. While some countries, with double digit growth rates present tremendous opportunities, there are also many obstacles that need to be overcome.

Fast economic growth, increasing economic and political stability coupled with tremendous patient potential and increased Westernization of lifestyle present new opportunities for global pharmaceutical companies. Despite problematic intellectual property protection high market potential is attracting most multinational pharmaceutical companies.

Healthcare system characteristics differ greatly between different emerging market countries. Greater state participation in healthcare provision is observed in all markets although growing disposable income and out-of-pocket expenditure are contributing to market growth.

The changing medical needs of the emerging countries are favoring multinational companies: sales of anti-infective agents are slowing down and cancer drugs, immunomodulatory and respiratory drugs among others are growing at fast rates. With increasing purchasing power consumer preference for expensive new treatments is growing.

Read more...